---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-039412"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T10:04:25.634951+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Galectin Q2 net loss $9.2M; NAVIGATE trial interim analysis expected Q4 2024

## Summary
- Net loss per share $0.15 for Q2 2023 vs $0.16 in Q2 2022; R&D expenses $7.4M down from $8.1M.
- Cash and equivalents $18.0M as of June 30, 2023; additional $30M available under chairman's credit line.
- NAVIGATE trial (NASH cirrhosis) fully randomized with 357 patients; Phase 2b interim analysis expected Q4 2024.
- Company evaluating Phase 2 trial of belapectin plus Keytruda in advanced head and neck cancers.
- Belapectin safety profile remains encouraging; no approved therapy for NASH cirrhosis with portal hypertension.

## SEC filing metadata
- accession: 0001140361-23-039412
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036123039412/0001140361-23-039412-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036123039412/brhc20057380_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-039412
- JSON: https://secwatch.observer/filing/0001140361-23-039412.json
- Plain text: https://secwatch.observer/filing/0001140361-23-039412.txt

## Key facts
- Earnings Releases
  GALECTIN THERAPEUTICS INC reported the three months ended June 30, 2023 results: net income a net loss applicable to common stockholders of $9.2 million, or ($0.15) per share, EPS ($0.15) per share.
  - Period: the three months ended June 30, 2023
  - Net income: a net loss applicable to common stockholders of $9.2 million, or ($0.15) per share
  - EPS: ($0.15) per share
  - Result: reported results
  source text: For the three months ended June 30, 2023, the Company reported a net loss applicable to common stockholders of $9.2 million, or ($0.15) per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133416/000114036123039412/0001140361-23-039412-index.htm
- Earnings Releases
  GALECTIN THERAPEUTICS INC reported financial results for the six months ended June 30, 2023.
  - Period: the six months ended June 30, 2023
  - Result: reported results
  source text: announcing its results of operations and financial condition as of and for the three and six months ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133416/000114036123039412/0001140361-23-039412-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.